Drugs / Recombinant adenoviral serotype 5 (rAD5) vector vaccine
Recombinant adenoviral serotype 5 (rAD5) vector vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00865566 | May 2009 → Oct 2017 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant adenoviral serotype 5 (rAD5) vector vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00865566 ↗ |
| Modality | Vaccine | “recombinant adenoviral serotype vector vaccine” NCT00865566 ↗ |
| Route | Intramuscular | “1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid” NCT00865566 ↗ |